Adiponectin: Merely a bystander or the missing link to cardiovascular disease?

Current Topics in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 139-163

  Hatzis, Georgios ^b   Deftereos, Spyridon ^a   Tousoulis, Dimitris ^b   Bouras, Georgios ^a   Giannopoulos, Georgios ^a   Anatoliotakis, Nikolaos ^a   Tsounis, Dimitrios ^a   Stefanadis, Christodoulos ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adiponectin; Biomarker; Cardiovascular disease; Coronary artery disease; Diabetes mellitus; Heart failure; Hypertension; Metabolic syndrome; Obesity

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; CCAAT ENHANCER BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; ENERGY METABOLISM; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; REVIEW; RISK FACTOR; SMOKING;

ADIPONECTIN; AGING; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DIABETES MELLITUS; HEART FAILURE; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SMOKING; TRANSCRIPTION FACTORS;

EID: 84877802223     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313020005     Document Type: Review

References (397)

1. Ezzati, M.; Lopez, A. D.; Rodgers, A.; Vander Hoorn, S.; Murray, C. J. Selected major risk factors and global and regional burden of disease. Lancet, 2002, 360, 1347-1360.
2. Ezzati, M.; Lopez, A. D. Estimates of global mortality attributable to smoking in 2000. Lancet, 2003, 362, 847-852.
3. Yach, D.; Hawkes, C.; Gould, C. L.; Hofman, K. J. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA, 2004, 291, 2616-2622.
4. Tilg, H.; Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 2006, 6, 772-783.
5. Xu, A.; Vanhoutte, P. M. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol, 302, H1231-1240.
6. Xu, A.; Wang, Y.; Lam, K. S.; Vanhoutte, P. M. Vascular actions of adipokines molecular mechanisms and therapeutic implications. Adv Pharmacol, 60, 229-255.
7. Berg, A. H.; Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res, 2005, 96, 939-949.
8. Matsuda, M.; Shimomura, I.; Sata, M.; Arita, Y.; Nishida, M.; Maeda, N.; Kumada, M.; Okamoto, Y.; Nagaretani, H.; Nishizawa, H.; Kishida, K.; Komuro, R.; Ouchi, N.; Kihara, S.; Nagai, R.; Funahashi, T.; Matsuzawa, Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem, 2002, 277, 37487-37491.
9. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K.; Sakai, N.; Shimomura, I.; Kobayashi, H.; Terasaka, N.; Inaba, T.; Funahashi, T.; Matsuzawa, Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2002, 106, 2767-2770.
10. Scherer, P. E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes, 2006, 55, 1537-1545.
11. Hertzel, A. V.; Smith, L. A.; Berg, A. H.; Cline, G. W.; Shulman, G. I.; Scherer, P. E.; Bernlohr, D. A. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am J Physiol Endocrinol Metab, 2006, 290, E814-823.
12. Kadowaki, T.; Yamauchi, T.; Kubota, N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett, 2008, 582, 74-80.
13. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100, 2473-2476.
14. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMPdependent pathway. Circulation, 2000, 102, 1296-1301.
15. Kizer, J. R.; Benkeser, D.; Arnold, A. M.; Djousse, L.; Zieman, S. J.; Mukamal, K. J.; Tracy, R. P.; Mantzoros, C. S.; Siscovick, D. S.; Gottdiener, J. S.; Ix, J. H. Total and High-Molecular-Weight Adiponectin and Risk of Coronary Heart Disease and Ischemic Stroke in Older Adults. J Clin Endocrinol Metab.
16. Heidemann, C.; Sun, Q.; van Dam, R. M.; Meigs, J. B.; Zhang, C.; Tworoger, S. S.; Mantzoros, C. S.; Hu, F. B. Total and highmolecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med, 2008, 149, 307-316.
17. Ohashi, K.; Ouchi, N.; Matsuzawa, Y. Adiponectin and hypertension. Am J Hypertens, 24, 263-269.
18. Djousse, L.; Wilk, J. B.; Hanson, N. Q.; Glynn, R. J.; Tsai, M. Y.; Gaziano, J. M. Association Between Adiponectin and Heart Failure Risk in the Physicians' Health Study. Obesity (Silver Spring).
19. McCormick, M. Letter to the Editor: Obesity and Inflammation: Change in Adiponectin, C-Reactive Protein, Tumour Necrosis Factor-Alpha and Interleukin-6 After Bariatric Surgery. Obes Surg.
20. Kishida, K.; Funahashi, T.; Shimomura, I. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets, 12, 118-131.
21. Kumada, M.; Kihara, S.; Sumitsuji, S.; Kawamoto, T.; Matsumoto, S.; Ouchi, N.; Arita, Y.; Okamoto, Y.; Shimomura, I.; Hiraoka, H.; Nakamura, T.; Funahashi, T.; Matsuzawa, Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol, 2003, 23, 85-89.
22. Salmenniemi, U.; Ruotsalainen, E.; Pihlajamaki, J.; Vauhkonen, I.; Kainulainen, S.; Punnonen, K.; Vanninen, E.; Laakso, M. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation, 2004, 110, 3842-3848.
23. Han, S. H.; Quon, M. J.; Kim, J. A.; Koh, K. K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol, 2007, 49, 531-538.
24. Kusminski, C. M.; McTernan, P. G.; Schraw, T.; Kos, K.; O'Hare, J. P.; Ahima, R.; Kumar, S.; Scherer, P. E. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia, 2007, 50, 634-642.
25. Psilopanagioti, A.; Papadaki, H.; Kranioti, E. F.; Alexandrides, T. K.; Varakis, J. N. Expression of adiponectin and adiponectin receptors in human pituitary gland and brain. Neuroendocrinology, 2009, 89, 38-47.
26. Thundyil, J.; Pavlovski, D.; Sobey, C. G.; Arumugam, T. V. Adiponectin receptor signalling in the brain. Br J Pharmacol, 165, 313-327.
27. Kubota, N.; Yano, W.; Kubota, T.; Yamauchi, T.; Itoh, S.; Kumagai, H.; Kozono, H.; Takamoto, I.; Okamoto, S.; Shiuchi, T.; Suzuki, R.; Satoh, H.; Tsuchida, A.; Moroi, M.; Sugi, K.; Noda, T.; Ebinuma, H.; Ueta, Y.; Kondo, T.; Araki, E.; Ezaki, O.; Nagai, R.; Tobe, K.; Terauchi, Y.; Ueki, K.; Minokoshi, Y.; Kadowaki, T. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab, 2007, 6, 55-68.
28. Delort, L.; Jarde, T.; Dubois, V.; Vasson, M. P.; Caldefie-Chezet, F. New insights into anticarcinogenic properties of adiponectin: a potential therapeutic approach in breast cancer? Vitam Horm, 90, 397-417.
29. Perrier, S.; Jarde, T. Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem.
30. Al-Harithy, R. N.; Al-Zahrani, M. H. The adiponectin gene, ADIPOQ, and genetic susceptibility to colon cancer. Oncol Lett, 3, 176-180.
31. Scherer, P. E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995, 270, 26746-26749.
32. Viengchareun, S.; Zennaro, M. C.; Pascual-Le Tallec, L.; Lombes, M. Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett, 2002, 532, 345-350.
33. Delaigle, A. M.; Jonas, J. C.; Bauche, I. B.; Cornu, O.; Brichard, S. M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology, 2004, 145, 5589-5597.
34. Yoda-Murakami, M.; Taniguchi, M.; Takahashi, K.; Kawamata, S.; Saito, K.; Choi-Miura, N. H.; Tomita, M. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun, 2001, 285, 372-377.
35. Pineiro, R.; Iglesias, M. J.; Gallego, R.; Raghay, K.; Eiras, S.; Rubio, J.; Dieguez, C.; Gualillo, O.; Gonzalez-Juanatey, J. R.; Lago, F. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett, 2005, 579, 5163-5169.
36. Berner, H. S.; Lyngstadaas, S. P.; Spahr, A.; Monjo, M.; Thommesen, L.; Drevon, C. A.; Syversen, U.; Reseland, J. E. Adiponectin and its receptors are expressed in bone-forming cells. Bone, 2004, 35, 842-849.
37. Katsiougiannis, S.; Kapsogeorgou, E. K.; Manoussakis, M. N.; Skopouli, F. N. Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum, 2006, 54, 2295-2299.
38. Caminos, J. E.; Nogueiras, R.; Gallego, R.; Bravo, S.; Tovar, S.; Garcia-Caballero, T.; Casanueva, F. F.; Dieguez, C. Expression and regulation of adiponectin and receptor in human and rat placenta. J Clin Endocrinol Metab, 2005, 90, 4276-4286.
39. Neumeier, M.; Weigert, J.; Buettner, R.; Wanninger, J.; Schaffler, A.; Muller, A. M.; Killian, S.; Sauerbruch, S.; Schlachetzki, F.; Steinbrecher, A.; Aslanidis, C.; Scholmerich, J.; Buechler, C. Detection of adiponectin in cerebrospinal fluid in humans. Am J Physiol Endocrinol Metab, 2007, 293, E965-969.
40. Crawford, L. J.; Peake, R.; Price, S.; Morris, T. C.; Irvine, A. E. Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. J Leukoc Biol, 88, 807-811.
41. Antoniades, C.; Antonopoulos, A. S.; Tousoulis, D.; Stefanadis, C. Adiponectin: from obesity to cardiovascular disease. Obes Rev, 2009, 10, 269-279.
42. Das, K.; Lin, Y.; Widen, E.; Zhang, Y.; Scherer, P. E. Chromosomal localization, expression pattern, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem Biophys Res Commun, 2001, 280, 1120-1129.
43. Iwaki, M.; Matsuda, M.; Maeda, N.; Funahashi, T.; Matsuzawa, Y.; Makishima, M.; Shimomura, I. Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 2003, 52, 1655-1663.
44. Park, S. K.; Oh, S. Y.; Lee, M. Y.; Yoon, S.; Kim, K. S.; Kim, J. W. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes, 2004, 53, 2757-2766.
45. Segawa, K.; Matsuda, M.; Fukuhara, A.; Morita, K.; Okuno, Y.; Komuro, R.; Shimomura, I. Identification of a novel distal enhancer in human adiponectin gene. J Endocrinol, 2009, 200, 107-116.
46. Qiao, L.; Maclean, P. S.; Schaack, J.; Orlicky, D. J.; Darimont, C.; Pagliassotti, M.; Friedman, J. E.; Shao, J. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes, 2005, 54, 1744-1754.
47. Kita, A.; Yamasaki, H.; Kuwahara, H.; Moriuchi, A.; Fukushima, K.; Kobayashi, M.; Fukushima, T.; Takahashi, R.; Abiru, N.; Uotani, S.; Kawasaki, E.; Eguchi, K. Identification of the promoter region required for human adiponectin gene transcription: Association with CCAAT/enhancer binding protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun, 2005, 331, 484-490.
48. Shapiro, L.; Scherer, P. E. The crystal structure of a complement1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol, 1998, 8, 335-338.
49. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N. H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R.; Kadowaki, T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423, 762-769.
50. Whitehead, J. P.; Richards, A. A.; Hickman, I. J.; Macdonald, G. A.; Prins, J. B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab, 2006, 8, 264-280.
51. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999, 257, 79-83.
52. Vaiopoulos, A. G.; Marinou, K.; Christodoulides, C.; Koutsilieris, M. The role of adiponectin in human vascular physiology. Int J Cardiol, 155, 188-193.
53. Matsuzawa, Y.; Funahashi, T.; Kihara, S.; Shimomura, I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol, 2004, 24, 29-33.
54. Gardener, H.; Crisby, M.; Sjoberg, C.; Hudson, B.; Goldberg, R.; Mendez, A. J.; Wright, C. B.; Rundek, T.; Elkind, M. S.; Sacco, R. L. Serum Adiponectin in Relation to Race-Ethnicity and Vascular Risk Factors in the Northern Manhattan Study. Metab Syndr Relat Disord.
55. Nishizawa, H.; Shimomura, I.; Kishida, K.; Maeda, N.; Kuriyama, H.; Nagaretani, H.; Matsuda, M.; Kondo, H.; Furuyama, N.; Kihara, S.; Nakamura, T.; Tochino, Y.; Funahashi, T.; Matsuzawa, Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes, 2002, 51, 2734-2741.
56. Combs, T. P.; Berg, A. H.; Rajala, M. W.; Klebanov, S.; Iyengar, P.; Jimenez-Chillaron, J. C.; Patti, M. E.; Klein, S. L.; Weinstein, R. S.; Scherer, P. E. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes, 2003, 52, 268-276.
57. Waki, H.; Yamauchi, T.; Kamon, J.; Kita, S.; Ito, Y.; Hada, Y.; Uchida, S.; Tsuchida, A.; Takekawa, S.; Kadowaki, T. Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology, 2005, 146, 790-796.
58. Fruebis, J.; Tsao, T. S.; Javorschi, S.; Ebbets-Reed, D.; Erickson, M. R.; Yen, F. T.; Bihain, B. E.; Lodish, H. F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A, 2001, 98, 2005-2010.
59. Simpson, F.; Whitehead, J. P. Adiponectin-it's all about the modifications. Int J Biochem Cell Biol, 42, 785-788.
60. Tsao, T. S.; Tomas, E.; Murrey, H. E.; Hug, C.; Lee, D. H.; Ruderman, N. B.; Heuser, J. E.; Lodish, H. F. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem, 2003, 278, 50810-50817.
61. Waki, H.; Yamauchi, T.; Kamon, J.; Ito, Y.; Uchida, S.; Kita, S.; Hara, K.; Hada, Y.; Vasseur, F.; Froguel, P.; Kimura, S.; Nagai, R.; Kadowaki, T. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem, 2003, 278, 40352-40363.
62. Schraw, T.; Wang, Z. V.; Halberg, N.; Hawkins, M.; Scherer, P. E. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology, 2008, 149, 2270-2282.
63. Radjainia, M.; Wang, Y.; Mitra, A. K. Structural polymorphism of oligomeric adiponectin visualized by electron microscopy. J Mol Biol, 2008, 381, 419-430.
64. Pajvani, U. B.; Hawkins, M.; Combs, T. P.; Rajala, M. W.; Doebber, T.; Berger, J. P.; Wagner, J. A.; Wu, M.; Knopps, A.; Xiang, A. H.; Utzschneider, K. M.; Kahn, S. E.; Olefsky, J. M.; Buchanan, T. A.; Scherer, P. E. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem, 2004, 279, 12152-12162.
65. Kobayashi, H.; Ouchi, N.; Kihara, S.; Walsh, K.; Kumada, M.; Abe, Y.; Funahashi, T.; Matsuzawa, Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res, 2004, 94, e27-31.
66. Yamauchi, T.; Kadowaki, T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond), 2008, 32 Suppl 7, S13-18.
67. Taddese, B.; Simpson, L. M.; Wall, I. D.; Blaney, F. E.; Kidley, N. J.; Clark, H. S.; Smith, R. E.; Upton, G. J.; Gouldson, P. R.; Psaroudakis, G.; Bywater, R. P.; Reynolds, C. A. G-proteincoupled receptor dynamics: dimerization and activation models compared with experiment. Biochem Soc Trans, 40, 394-399.
68. Trzaskowski, B.; Latek, D.; Yuan, S.; Ghoshdastider, U.; Debinski, A.; Filipek, S. Action of molecular switches in GPCRs-theoretical and experimental studies. Curr Med Chem, 19, 1090-1109.
69. Wess, J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J, 1997, 11, 346-354.
70. Yokomizo, T.; Izumi, T.; Chang, K.; Takuwa, Y.; Shimizu, T. A Gprotein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature, 1997, 387, 620-624.
71. Buechler, C.; Wanninger, J.; Neumeier, M. Adiponectin receptor binding proteins-recent advances in elucidating adiponectin signalling pathways. FEBS Lett, 584, 4280-4286.
72. Lee, M. H.; Klein, R. L.; El-Shewy, H. M.; Luttrell, D. K.; Luttrell, L. M. The adiponectin receptors AdipoR1 and AdipoR2 activate ERK1/2 through a Src/Ras-dependent pathway and stimulate cell growth. Biochemistry, 2008, 47, 11682-11692.
73. Yamauchi, T.; Nio, Y.; Maki, T.; Kobayashi, M.; Takazawa, T.; Iwabu, M.; Okada-Iwabu, M.; Kawamoto, S.; Kubota, N.; Kubota, T.; Ito, Y.; Kamon, J.; Tsuchida, A.; Kumagai, K.; Kozono, H.; Hada, Y.; Ogata, H.; Tokuyama, K.; Tsunoda, M.; Ide, T.; Murakami, K.; Awazawa, M.; Takamoto, I.; Froguel, P.; Hara, K.; Tobe, K.; Nagai, R.; Ueki, K.; Kadowaki, T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med, 2007, 13, 332-339.
74. Miaczynska, M.; Christoforidis, S.; Giner, A.; Shevchenko, A.; Uttenweiler-Joseph, S.; Habermann, B.; Wilm, M.; Parton, R. G.; Zerial, M. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell, 2004, 116, 445-456.
75. Wang, C.; Xin, X.; Xiang, R.; Ramos, F. J.; Liu, M.; Lee, H. J.; Chen, H.; Mao, X.; Kikani, C. K.; Liu, F.; Dong, L. Q. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem, 2009, 284, 31608-31615.
76. Hardie, D. G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond), 2008, 32 Suppl 4, S7-12.
77. Zhou, L.; Deepa, S. S.; Etzler, J. C.; Ryu, J.; Mao, X.; Fang, Q.; Liu, D. D.; Torres, J. M.; Jia, W.; Lechleiter, J. D.; Liu, F.; Dong, L. Q. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinasedependent pathways. J Biol Chem, 2009, 284, 22426-22435.
78. Deepa, S. S.; Dong, L. Q. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab, 2009, 296, E22-36.
79. Wanninger, J.; Neumeier, M.; Weigert, J.; Bauer, S.; Weiss, T. S.; Schaffler, A.; Krempl, C.; Bleyl, C.; Aslanidis, C.; Scholmerich, J.; Buechler, C. Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol, 2009, 297, G611-618.
80. Chandrasekar, B.; Boylston, W. H.; Venkatachalam, K.; Webster, N. J.; Prabhu, S. D.; Valente, A. J. Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem, 2008, 283, 24889-24898.
81. Hug, C.; Wang, J.; Ahmad, N. S.; Bogan, J. S.; Tsao, T. S.; Lodish, H. F. T-cadherin is a receptor for hexameric and high-molecularweight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A, 2004, 101, 10308-10313.
82. Guerre-Millo, M. Adiponectin: an update. Diabetes Metab, 2008, 34, 12-18.
83. Komura, N.; Kihara, S.; Sonoda, M.; Maeda, N.; Tochino, Y.; Funahashi, T.; Shimomura, I. Increment and impairment of adiponectin in renal failure. Cardiovasc Res, 86, 471-477.
84. Shen, Y. Y.; Charlesworth, J. A.; Kelly, J. J.; Peake, P. W. The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism, 2007, 56, 1201-1208.
85. Halberg, N.; Schraw, T. D.; Wang, Z. V.; Kim, J. Y.; Yi, J.; Hamilton, M. P.; Luby-Phelps, K.; Scherer, P. E. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes, 2009, 58, 1961-1970.
86. Gavrila, A.; Peng, C. K.; Chan, J. L.; Mietus, J. E.; Goldberger, A. L.; Mantzoros, C. S. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab, 2003, 88, 2838-2843.
87. Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev, 2006, 58, 726-741.
88. Berger, J.; Moller, D. E. The mechanisms of action of PPARs. Annu Rev Med, 2002, 53, 409-435.
89. Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res, 2006, 45, 120-159.
90. Yu, J. G.; Javorschi, S.; Hevener, A. L.; Kruszynska, Y. T.; Norman, R. A.; Sinha, M.; Olefsky, J. M. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes, 2002, 51, 2968-2974.
91. Qiang, L.; Wang, H.; Farmer, S. R. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol, 2007, 27, 4698-4707.
92. Banga, A.; Unal, R.; Tripathi, P.; Pokrovskaya, I.; Owens, R. J.; Kern, P. A.; Ranganathan, G. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab, 2009, 296, E480-489.
93. Rasouli, N.; Yao-Borengasser, A.; Miles, L. M.; Elbein, S. C.; Kern, P. A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab, 2006, 290, E42-E46.
94. Liu, M.; Zhou, L.; Xu, A.; Lam, K. S.; Wetzel, M. D.; Xiang, R.; Zhang, J.; Xin, X.; Dong, L. Q.; Liu, F. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc Natl Acad Sci U S A, 2008, 105, 18302-18307.
95. Galili, N.; Davis, R. J.; Fredericks, W. J.; Mukhopadhyay, S.; Rauscher, F. J., 3rd; Emanuel, B. S.; Rovera, G.; Barr, F. G. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet, 1993, 5, 230-235.
96. Daitoku, H.; Fukamizu, A. FOXO transcription factors in the regulatory networks of longevity. J Biochem, 2007, 141, 769-774.
97. Nakae, J.; Kitamura, T.; Kitamura, Y.; Biggs, W. H., 3rd; Arden, K. C.; Accili, D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell, 2003, 4, 119-129.
98. Guo, S.; Rena, G.; Cichy, S.; He, X.; Cohen, P.; Unterman, T. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulinlike growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem, 1999, 274, 17184-17192.
99. Liang, F.; Kume, S.; Koya, D. SIRT1 and insulin resistance. Nat Rev Endocrinol, 2009, 5, 367-373.
100. Banks, A. S.; Kon, N.; Knight, C.; Matsumoto, M.; Gutierrez-Juarez, R.; Rossetti, L.; Gu, W.; Accili, D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab, 2008, 8, 333-341.
101. Frescas, D.; Valenti, L.; Accili, D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem, 2005, 280, 20589-20595.
102. Qiao, L.; Shao, J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem, 2006, 281, 39915-39924.
103. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; Machado De Oliveira, R.; Leid, M.; McBurney, M. W.; Guarente, L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 2004, 429, 771-776.
104. Nakae, J.; Cao, Y.; Oki, M.; Orba, Y.; Sawa, H.; Kiyonari, H.; Iskandar, K.; Suga, K.; Lombes, M.; Hayashi, Y. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes, 2008, 57, 563-576.
105. Fan, W.; Imamura, T.; Sonoda, N.; Sears, D. D.; Patsouris, D.; Kim, J. J.; Olefsky, J. M. FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes. J Biol Chem, 2009, 284, 12188-12197.
106. Yokoyama, C.; Wang, X.; Briggs, M. R.; Admon, A.; Wu, J.; Hua, X.; Goldstein, J. L.; Brown, M. S. SREBP-1, a basic-helix-loophelix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell, 1993, 75, 187-197.
107. Wang, X.; Sato, R.; Brown, M. S.; Hua, X.; Goldstein, J. L. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell, 1994, 77, 53-62.
108. Gasic, G. P. Basic-helix-loop-helix transcription factor and sterol sensor in a single membrane-bound molecule. Cell, 1994, 77, 17-19.
109. Seo, J. B.; Moon, H. M.; Noh, M. J.; Lee, Y. S.; Jeong, H. W.; Yoo, E. J.; Kim, W. S.; Park, J.; Youn, B. S.; Kim, J. W.; Park, S. D.; Kim, J. B. Adipocyte determination- and differentiationdependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem, 2004, 279, 22108-22117.
110. Doran, A. C.; Meller, N.; Cutchins, A.; Deliri, H.; Slayton, R. P.; Oldham, S. N.; Kim, J. B.; Keller, S. R.; McNamara, C. A. The helix-loop-helix factors Id3 and E47 are novel regulators of adiponectin. Circ Res, 2008, 103, 624-634.
111. Shimomura, I.; Bashmakov, Y.; Horton, J. D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem, 1999, 274, 30028-30032.
112. Shimomura, I.; Matsuda, M.; Hammer, R. E.; Bashmakov, Y.; Brown, M. S.; Goldstein, J. L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell, 2000, 6, 77-86.
113. Becard, D.; Hainault, I.; Azzout-Marniche, D.; Bertry-Coussot, L.; Ferre, P.; Foufelle, F. Adenovirus-mediated overexpression of sterol regulatory element binding protein-1c mimics insulin effects on hepatic gene expression and glucose homeostasis in diabetic mice. Diabetes, 2001, 50, 2425-2430.
114. Shimano, H.; Yahagi, N.; Amemiya-Kudo, M.; Hasty, A. H.; Osuga, J.; Tamura, Y.; Shionoiri, F.; Iizuka, Y.; Ohashi, K.; Harada, K.; Gotoda, T.; Ishibashi, S.; Yamada, N. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem, 1999, 274, 35832-35839.
115. Kovacs, K. A.; Steinmann, M.; Magistretti, P. J.; Halfon, O.; Cardinaux, J. R. CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation. J Biol Chem, 2003, 278, 36959-36965.
116. Nerlov, C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol, 2007, 17, 318-324.
117. Park, B. H.; Qiang, L.; Farmer, S. R. Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol Cell Biol, 2004, 24, 8671-8680.
118. Gustafson, B.; Jack, M. M.; Cushman, S. W.; Smith, U. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun, 2003, 308, 933-939.
119. Barth, N.; Langmann, T.; Scholmerich, J.; Schmitz, G.; Schaffler, A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia, 2002, 45, 1425-1433.
120. Dubois, S. G.; Heilbronn, L. K.; Smith, S. R.; Albu, J. B.; Kelley, D. E.; Ravussin, E. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes. Obesity (Silver Spring), 2006, 14, 1543-1552.
121. Yang, X.; Jansson, P. A.; Nagaev, I.; Jack, M. M.; Carvalho, E.; Sunnerhagen, K. S.; Cam, M. C.; Cushman, S. W.; Smith, U. Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun, 2004, 317, 1045-1051.
122. Yang, X.; Enerback, S.; Smith, U. Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obes Res, 2003, 11, 1182-1191.
123. Olofsson, L. E.; Orho-Melander, M.; William-Olsson, L.; Sjoholm, K.; Sjostrom, L.; Groop, L.; Carlsson, B.; Carlsson, L. M.; Olsson, B. CCAAT/enhancer binding protein alpha (C/EBP-alpha) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPalpha is associated with serum levels of triglycerides. J Clin Endocrinol Metab, 2008, 93, 4880-4886.
124. Zhu, M.; Miura, J.; Lu, L. X.; Bernier, M.; DeCabo, R.; Lane, M. A.; Roth, G. S.; Ingram, D. K. Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. Exp Gerontol, 2004, 39, 1049-1059.
125. Bourtchuladze, R.; Frenguelli, B.; Blendy, J.; Cioffi, D.; Schutz, G.; Silva, A. J. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell, 1994, 79, 59-68.
126. Montminy, M. R.; Bilezikjian, L. M. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature, 1987, 328, 175-178.
127. Saura, C. A. CREB-regulated transcription coactivator 1-dependent transcription in Alzheimer's disease mice. Neurodegener Dis, 10, 250-252.
128. Dentin, R.; Hedrick, S.; Xie, J.; Yates, J., 3rd; Montminy, M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science, 2008, 319, 1402-1405.
129. Dentin, R.; Liu, Y.; Koo, S. H.; Hedrick, S.; Vargas, T.; Heredia, J.; Yates, J., 3rd; Montminy, M. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature, 2007, 449, 366-369.
130. Herzig, S.; Long, F.; Jhala, U. S.; Hedrick, S.; Quinn, R.; Bauer, A.; Rudolph, D.; Schutz, G.; Yoon, C.; Puigserver, P.; Spiegelman, B.; Montminy, M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature, 2001, 413, 179-183.
131. Qi, L.; Saberi, M.; Zmuda, E.; Wang, Y.; Altarejos, J.; Zhang, X.; Dentin, R.; Hedrick, S.; Bandyopadhyay, G.; Hai, T.; Olefsky, J.; Montminy, M. Adipocyte CREB promotes insulin resistance in obesity. Cell Metab, 2009, 9, 277-286.
132. Kim, H. B.; Kong, M.; Kim, T. M.; Suh, Y. H.; Kim, W. H.; Lim, J. H.; Song, J. H.; Jung, M. H. NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes, 2006, 55, 1342-1352.
133. Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol, 2005, 5, 472-484.
134. Hoey, T.; Sun, Y. L.; Williamson, K.; Xu, X. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity, 1995, 2, 461-472.
135. Ho, I. C.; Kim, J. H.; Rooney, J. W.; Spiegelman, B. M.; Glimcher, L. H. A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc Natl Acad Sci U S A, 1998, 95, 15537-15541.
136. Ziegler, M. G.; Elayan, H.; Milic, M.; Sun, P.; Gharaibeh, M. Epinephrine and the metabolic syndrome. Curr Hypertens Rep, 14, 1-7.
137. Ebert, S. N.; Rong, Q.; Boe, S.; Thompson, R. P.; Grinberg, A.; Pfeifer, K. Targeted insertion of the Cre-recombinase gene at the phenylethanolamine n-methyltransferase locus: a new model for studying the developmental distribution of adrenergic cells. Dev Dyn, 2004, 231, 849-858.
138. Fasshauer, M.; Klein, J.; Neumann, S.; Eszlinger, M.; Paschke, R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett, 2001, 507, 142-146.
139. de Silva, H. C.; Firth, S. M.; Twigg, S. M.; Baxter, R. C. Interaction Between IGF Binding Protein-3 and TGFbeta in the Regulation of Adipocyte Differentiation. Endocrinology, 153, 4799-4807.
140. Watanabe, S.; Tamura, T.; Ono, K.; Horiuchi, H.; Kimura, T.; Kita, T.; Furukawa, Y. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail, 12, 1214-1222.
141. Zappala, G.; Rechler, M. M. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochem Biophys Res Commun, 2009, 382, 785-789.
142. Bes-Houtmann, S.; Roche, R.; Hoareau, L.; Gonthier, M. P.; Festy, F.; Caillens, H.; Gasque, P.; Lefebvre d'Hellencourt, C.; Cesari, M. Presence of functional TLR2 and TLR4 on human adipocytes. Histochem Cell Biol, 2007, 127, 131-137.
143. Hoareau, L.; Bencharif, K.; Rondeau, P.; Murumalla, R.; Ravanan, P.; Tallet, F.; Delarue, P.; Cesari, M.; Roche, R.; Festy, F. Signaling pathways involved in LPS induced TNFalpha production in human adipocytes. J Inflamm (Lond), 7, 1.
144. Foreback, J. L.; Sarma, V.; Yeager, N. R.; Younkin, E. M.; Remick, D. G.; Ward, P. A. Blood mononuclear cell production of TNF-alpha and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway. J Leukoc Biol, 1998, 64, 124-133.
145. von Fliedner, V.; Miescher, S.; Gerain, J.; Gallati, H.; Barras, C.; Heumann, D.; Cerottini, J. C. Production of tumor necrosis factoralpha by naive or memory T lymphocytes activated via CD28. Cell Immunol, 1992, 139, 198-207.
146. Kern, P. A.; Ranganathan, S.; Li, C.; Wood, L.; Ranganathan, G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab, 2001, 280, E745-751.
147. Kern, P. A.; Saghizadeh, M.; Ong, J. M.; Bosch, R. J.; Deem, R.; Simsolo, R. B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest, 1995, 95, 2111-2119.
148. Park, H. J.; Kang, Y. M.; Kim, C. H.; Jung, M. H. ATF3 negatively regulates adiponectin receptor 1 expression. Biochem Biophys Res Commun, 400, 72-77.
149. Lim, J. Y.; Kim, W. H.; Park, S. I. GO6976 prevents TNF-alphainduced suppression of adiponectin expression in 3T3-L1 adipocytes: putative involvement of protein kinase C. FEBS Lett, 2008, 582, 3473-3478.
150. Ron, D.; Brasier, A. R.; McGehee, R. E., Jr.; Habener, J. F. Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest, 1992, 89, 223-233.
151. Moller, D. E.; Berger, J. P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord, 2003, 27 Suppl 3, S17-21.
152. Zhang, B.; Berger, J.; Hu, E.; Szalkowski, D.; White-Carrington, S.; Spiegelman, B. M.; Moller, D. E. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factoralpha. Mol Endocrinol, 1996, 10, 1457-1466.
153. Sewter, C.; Berger, D.; Considine, R. V.; Medina, G.; Rochford, J.; Ciaraldi, T.; Henry, R.; Dohm, L.; Flier, J. S.; O'Rahilly, S.; Vidal-Puig, A. J. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes, 2002, 51, 1035-1041.
154. Denson, L. A.; Menon, R. K.; Shaufl, A.; Bajwa, H. S.; Williams, C. R.; Karpen, S. J. TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. J Clin Invest, 2001, 107, 1451-1458.
155. Scheller, J.; Chalaris, A.; Schmidt-Arras, D.; Rose-John, S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta, 1813, 878-888.
156. Yan, S. F.; Ogawa, S.; Stern, D. M.; Pinsky, D. J. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int, 1997, 51, 419-425.
157. Fried, S. K.; Bunkin, D. A.; Greenberg, A. S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab, 1998, 83, 847-850.
158. Fan, D.; Li, L.; Wang, C.; Cui, X. B.; Zhou, Y.; Wu, L. L. Adiponectin induces interleukin-6 production and its underlying mechanism in adult rat cardiac fibroblasts. J Cell Physiol, 226, 1793-1802.
159. Fernandez-Real, J. M.; Vayreda, M.; Richart, C.; Gutierrez, C.; Broch, M.; Vendrell, J.; Ricart, W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab, 2001, 86, 1154-1159.
160. Straub, R. H.; Hense, H. W.; Andus, T.; Scholmerich, J.; Riegger, G. A.; Schunkert, H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab, 2000, 85, 1340-1344.
161. Mohamed-Ali, V.; Goodrick, S.; Rawesh, A.; Katz, D. R.; Miles, J. M.; Yudkin, J. S.; Klein, S.; Coppack, S. W. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab, 1997, 82, 4196-4200.
162. Muller, S.; Martin, S.; Koenig, W.; Hanifi-Moghaddam, P.; Rathmann, W.; Haastert, B.; Giani, G.; Illig, T.; Thorand, B.; Kolb, H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia, 2002, 45, 805-812.
163. Kado, S.; Nagase, T.; Nagata, N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol, 1999, 36, 67-72.
164. Pickup, J. C.; Mattock, M. B.; Chusney, G. D.; Burt, D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997, 40, 1286-1292.
165. Fasshauer, M.; Kralisch, S.; Klier, M.; Lossner, U.; Bluher, M.; Klein, J.; Paschke, R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 2003, 301, 1045-1050.
166. Bruun, J. M.; Lihn, A. S.; Verdich, C.; Pedersen, S. B.; Toubro, S.; Astrup, A.; Richelsen, B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab, 2003, 285, E527-533.
167. Negi, S. I.; Pankow, J. S.; Fernstrom, K.; Hoogeveen, R. C.; Zhu, N.; Couper, D.; Schmidt, M. I.; Duncan, B. B.; Ballantyne, C. M. Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care, 35, 1513-1518.
168. Sun, L.; Hu, F. B.; Yu, Z.; Li, H.; Liu, H.; Wang, X.; Yu, D.; Wu, H.; Zhang, G.; Zong, G.; Liu, Y.; Lin, X. Lean body mass, interleukin 18, and metabolic syndrome in apparently healthy Chinese. PLoS One, 6, e18104.
169. Hivert, M. F.; Sun, Q.; Shrader, P.; Mantzoros, C. S.; Meigs, J. B.; Hu, F. B. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia, 2009, 52, 2101-2108.
170. Straczkowski, M.; Kowalska, I.; Nikolajuk, A.; Otziomek, E.; Adamska, A.; Karolczuk-Zarachowicz, M.; Gorska, M. Increased serum interleukin-18 concentration is associated with hypoadiponectinemia in obesity, independently of insulin resistance. Int J Obes (Lond), 2007, 31, 221-225.
171. Chandrasekar, B.; Patel, D. N.; Mummidi, S.; Kim, J. W.; Clark, R. A.; Valente, A. J. Interleukin-18 suppresses adiponectin expression in 3T3-L1 adipocytes via a novel signal transduction pathway involving ERK1/2-dependent NFATc4 phosphorylation. J Biol Chem, 2008, 283, 4200-4209.
172. Pajvani, U. B.; Du, X.; Combs, T. P.; Berg, A. H.; Rajala, M. W.; Schulthess, T.; Engel, J.; Brownlee, M.; Scherer, P. E. Structurefunction studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem, 2003, 278, 9073-9085.
173. Tsao, T. S.; Murrey, H. E.; Hug, C.; Lee, D. H.; Lodish, H. F. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem, 2002, 277, 29359-29362.
174. Wang, Y.; Lam, K. S.; Yau, M. H.; Xu, A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J, 2008, 409, 623-633.
175. Wang, Y.; Xu, A.; Knight, C.; Xu, L. Y.; Cooper, G. J. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem, 2002, 277, 19521-19529.
176. Richards, A. A.; Stephens, T.; Charlton, H. K.; Jones, A.; Macdonald, G. A.; Prins, J. B.; Whitehead, J. P. Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol, 2006, 20, 1673-1687.
177. Wang, Z. V.; Schraw, T. D.; Kim, J. Y.; Khan, T.; Rajala, M. W.; Follenzi, A.; Scherer, P. E. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol, 2007, 27, 3716-3731.
178. Ellgaard, L.; Ruddock, L. W. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep, 2005, 6, 28-32.
179. Pemble, S. E.; Wardle, A. F.; Taylor, J. B. Glutathione Stransferase class Kappa: characterization by the cloning of rat mitochondrial GST and identification of a human homologue. Biochem J, 1996, 319 (Pt 3), 749-754.
180. Gregor, M. F.; Hotamisligil, G. S. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res, 2007, 48, 1905-1914.
181. Han, K. L.; Choi, J. S.; Lee, J. Y.; Song, J.; Joe, M. K.; Jung, M. H.; Hwang, J. K. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes, 2008, 57, 737-745.
182. Koh, E. H.; Park, J. Y.; Park, H. S.; Jeon, M. J.; Ryu, J. W.; Kim, M.; Kim, S. Y.; Kim, M. S.; Kim, S. W.; Park, I. S.; Youn, J. H.; Lee, K. U. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes, 2007, 56, 2973-2981.
183. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun, 425, 560-564.
184. Lin, H.; Li, Z. Adiponectin self-regulates its expression and multimerization in adipose tissue: an autocrine/paracrine mechanism? Med Hypotheses, 78, 75-78.
185. Bedi, D.; Clarke, K. J.; Dennis, J. C.; Zhong, Q.; Brunson, B. L.; Morrison, E. E.; Judd, R. L. Endothelin-1 inhibits adiponectin secretion through a phosphatidylinositol 4,5-bisphosphate/actindependent mechanism. Biochem Biophys Res Commun, 2006, 345, 332-339.
186. Karastergiou, K.; Evans, I.; Ogston, N.; Miheisi, N.; Nair, D.; Kaski, J. C.; Jahangiri, M.; Mohamed-Ali, V. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol, 30, 1340-1346.
187. Hui, X.; Lam, K. S.; Vanhoutte, P. M.; Xu, A. Adiponectin and cardiovascular health: an update. Br J Pharmacol, 165, 574-590.
188. Cheng, K. K.; Lam, K. S.; Wang, Y.; Huang, Y.; Carling, D.; Wu, D.; Wong, C.; Xu, A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes, 2007, 56, 1387-1394.
189. Kim, J. E.; Song, S. E.; Kim, Y. W.; Kim, J. Y.; Park, S. C.; Park, Y. K.; Baek, S. H.; Lee, I. K.; Park, S. Y. Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol, 207, 35-44.
190. Motoshima, H.; Wu, X.; Mahadev, K.; Goldstein, B. J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun, 2004, 315, 264-271.
191. Plant, S.; Shand, B.; Elder, P.; Scott, R. Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diab Vasc Dis Res, 2008, 5, 102-108.
192. Devaraj, S.; Swarbrick, M. M.; Singh, U.; Adams-Huet, B.; Havel, P. J.; Jialal, I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol, 2008, 129, 815-822.
193. Devaraj, S.; Torok, N.; Dasu, M. R.; Samols, D.; Jialal, I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol, 2008, 28, 1368-1374.
194. Kobashi, C.; Urakaze, M.; Kishida, M.; Kibayashi, E.; Kobayashi, H.; Kihara, S.; Funahashi, T.; Takata, M.; Temaru, R.; Sato, A.; Yamazaki, K.; Nakamura, N.; Kobayashi, M. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res, 2005, 97, 1245-1252.
195. Wu, X.; Mahadev, K.; Fuchsel, L.; Ouedraogo, R.; Xu, S. Q.; Goldstein, B. J. Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab, 2007, 293, E1836-1844.
196. Szmitko, P. E.; Fedak, P. W.; Weisel, R. D.; Stewart, D. J.; Kutryk, M. J.; Verma, S. Endothelial progenitor cells: new hope for a broken heart. Circulation, 2003, 107, 3093-3100.
197. Seeger, F. H.; Haendeler, J.; Walter, D. H.; Rochwalsky, U.; Reinhold, J.; Urbich, C.; Rossig, L.; Corbaz, A.; Chvatchko, Y.; Zeiher, A. M.; Dimmeler, S. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation, 2005, 111, 1184-1191.
198. Sorrentino, S. A.; Bahlmann, F. H.; Besler, C.; Muller, M.; Schulz, S.; Kirchhoff, N.; Doerries, C.; Horvath, T.; Limbourg, A.; Limbourg, F.; Fliser, D.; Haller, H.; Drexler, H.; Landmesser, U. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation, 2007, 116, 163-173.
199. Li, M.; Kim, D. H.; Tsenovoy, P. L.; Peterson, S. J.; Rezzani, R.; Rodella, L. F.; Aronow, W. S.; Ikehara, S.; Abraham, N. G. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes, 2008, 57, 1526-1535.
200. Nakamura, N.; Naruse, K.; Matsuki, T.; Hamada, Y.; Nakashima, E.; Kamiya, H.; Matsubara, T.; Enomoto, A.; Takahashi, M.; Oiso, Y.; Nakamura, J. Adiponectin promotes migration activities of endothelial progenitor cells via Cdc42/Rac1. FEBS Lett, 2009, 583, 2457-2463.
201. Arita, Y.; Kihara, S.; Ouchi, N.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Kumada, M.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Shimomura, I.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105, 2893-2898.
202. Wang, Y.; Lam, K. S.; Xu, J. Y.; Lu, G.; Xu, L. Y.; Cooper, G. J.; Xu, A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem, 2005, 280, 18341-18347.
203. Yamaguchi, N.; Argueta, J. G.; Masuhiro, Y.; Kagishita, M.; Nonaka, K.; Saito, T.; Hanazawa, S.; Yamashita, Y. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett, 2005, 579, 6821-6826.
204. Kumada, M.; Kihara, S.; Ouchi, N.; Kobayashi, H.; Okamoto, Y.; Ohashi, K.; Maeda, K.; Nagaretani, H.; Kishida, K.; Maeda, N.; Nagasawa, A.; Funahashi, T.; Matsuzawa, Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation, 2004, 109, 2046-2049.
205. Park, P. H.; McMullen, M. R.; Huang, H.; Thakur, V.; Nagy, L. E. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem, 2007, 282, 21695-21703.
206. Furukawa, K.; Hori, M.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Miyazaki, A.; Nakayama, H.; Horiuchi, S. Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun, 2004, 317, 831-836.
207. Ouchi, N.; Kihara, S.; Arita, Y.; Nishida, M.; Matsuyama, A.; Okamoto, Y.; Ishigami, M.; Kuriyama, H.; Kishida, K.; Nishizawa, H.; Hotta, K.; Muraguchi, M.; Ohmoto, Y.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 2001, 103, 1057-1063.
208. Tsubakio-Yamamoto, K.; Matsuura, F.; Koseki, M.; Oku, H.; Sandoval, J. C.; Inagaki, M.; Nakatani, K.; Nakaoka, H.; Kawase, R.; Yuasa-Kawase, M.; Masuda, D.; Ohama, T.; Maeda, N.; Nakagawa-Toyama, Y.; Ishigami, M.; Nishida, M.; Kihara, S.; Shimomura, I.; Yamashita, S. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun, 2008, 375, 390-394.
209. Goldstein, B. J.; Scalia, R. G.; Ma, X. L. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med, 2009, 6, 27-35.
210. Ding, Q. F.; Hayashi, T.; Zhang, X. J.; Funami, J.; Ge, L.; Li, J.; Huang, X. L.; Cao, L.; Zhang, J.; Akihisa, I. Risks of CHD identified by different criteria of metabolic syndrome and related changes of adipocytokines in elderly postmenopausal women. J Diabetes Complications, 2007, 21, 315-319.
211. Tao, L.; Gao, E.; Jiao, X.; Yuan, Y.; Li, S.; Christopher, T. A.; Lopez, B. L.; Koch, W.; Chan, L.; Goldstein, B. J.; Ma, X. L. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation, 2007, 115, 1408-1416.
212. Wang, Y.; Gao, E.; Tao, L.; Lau, W. B.; Yuan, Y.; Goldstein, B. J.; Lopez, B. L.; Christopher, T. A.; Tian, R.; Koch, W.; Ma, X. L. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation, 2009, 119, 835-844.
213. Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. Endocr Rev, 2005, 26, 439-451.
214. Shibata, R.; Sato, K.; Pimentel, D. R.; Takemura, Y.; Kihara, S.; Ohashi, K.; Funahashi, T.; Ouchi, N.; Walsh, K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med, 2005, 11, 1096-1103.
215. Holland, W. L.; Miller, R. A.; Wang, Z. V.; Sun, K.; Barth, B. M.; Bui, H. H.; Davis, K. E.; Bikman, B. T.; Halberg, N.; Rutkowski, J. M.; Wade, M. R.; Tenorio, V. M.; Kuo, M. S.; Brozinick, J. T.; Zhang, B. B.; Birnbaum, M. J.; Summers, S. A.; Scherer, P. E. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med, 17, 55-63.
216. Gonon, A. T.; Widegren, U.; Bulhak, A.; Salehzadeh, F.; Persson, J.; Sjoquist, P. O.; Pernow, J. Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res, 2008, 78, 116-122.
217. Ikeda, Y.; Ohashi, K.; Shibata, R.; Pimentel, D. R.; Kihara, S.; Ouchi, N.; Walsh, K. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett, 2008, 582, 1147-1150.
218. Shimano, M.; Ouchi, N.; Shibata, R.; Ohashi, K.; Pimentel, D. R.; Murohara, T.; Walsh, K. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol, 49, 210-220.
219. Wareham, N. J.; Forouhi, N. G. Is there really an epidemic of diabetes? Diabetologia, 2005, 48, 1454-1455.
220. Wild, S. H.; Forouhi, N. G. What is the scale of the future diabetes epidemic, and how certain are we about it? Diabetologia, 2007, 50, 903-905.
221. King, H.; Aubert, R. E.; Herman, W. H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998, 21, 1414-1431.
222. Forouhi, N. G.; Merrick, D.; Goyder, E.; Ferguson, B. A.; Abbas, J.; Lachowycz, K.; Wild, S. H. Diabetes prevalence in England, 2001-estimates from an epidemiological model. Diabet Med, 2006, 23, 189-197.
223. Berg, A. H.; Combs, T. P.; Du, X.; Brownlee, M.; Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med, 2001, 7, 947-953.
224. Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.; Kondo, H.; Takahashi, M.; Arita, Y.; Komuro, R.; Ouchi, N.; Kihara, S.; Tochino, Y.; Okutomi, K.; Horie, M.; Takeda, S.; Aoyama, T.; Funahashi, T.; Matsuzawa, Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med, 2002, 8, 731-737.
225. Wannamethee, S. G.; Lowe, G. D.; Rumley, A.; Cherry, L.; Whincup, P. H.; Sattar, N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care, 2007, 30, 1200-1205.
226. Wannamethee, S. G.; Tchernova, J.; Whincup, P.; Lowe, G. D.; Rumley, A.; Brown, K.; Cherry, L.; Sattar, N. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond), 2007, 31, 1089-1098.
227. Valsamakis, G.; Chetty, R.; McTernan, P. G.; Al-Daghri, N. M.; Barnett, A. H.; Kumar, S. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab, 2003, 5, 131-135.
228. Tsubakio-Yamamoto, K.; Sugimoto, T.; Nishida, M.; Okano, R.; Monden, Y.; Kitazume-Taneike, R.; Yamashita, T.; Nakaoka, H.; Kawase, R.; Yuasa-Kawase, M.; Inagaki, M.; Nakatani, K.; Masuda, D.; Ohama, T.; Matsuyama, A.; Nakagawa-Toyama, Y.; Ishigami, M.; Komuro, I.; Yamashita, S. Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. Metabolism, 61, 1763-1770.
229. Bajaj, M.; Suraamornkul, S.; Piper, P.; Hardies, L. J.; Glass, L.; Cersosimo, E.; Pratipanawatr, T.; Miyazaki, Y.; DeFronzo, R. A. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazonetreated type 2 diabetic patients. J Clin Endocrinol Metab, 2004, 89, 200-206.
230. Li, S.; Shin, H. J.; Ding, E. L.; van Dam, R. M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 2009, 302, 179-188.
231. Tabak, A. G.; Carstensen, M.; Witte, D. R.; Brunner, E. J.; Shipley, M. J.; Jokela, M.; Roden, M.; Kivimaki, M.; Herder, C. Adiponectin Trajectories Before Type 2 Diabetes Diagnosis: Whitehall II study. Diabetes Care, 35, 2540-2547.
232. Mirza, S.; Hossain, M.; Mathews, C.; Martinez, P.; Pino, P.; Gay, J. L.; Rentfro, A.; McCormick, J. B.; Fisher-Hoch, S. P. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine, 57, 136-142.
233. Hanley, A. J.; Wagenknecht, L. E.; Norris, J. M.; Bergman, R.; Anderson, A.; Chen, Y. I.; Lorenzo, C.; Haffner, S. M. Adiponectin and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. Diabetes Care, 34, 2231-2236.
234. Jalovaara, K.; Santaniemi, M.; Timonen, M.; Jokelainen, J.; Kesaniemi, Y. A.; Ukkola, O.; Keinanen-Kiukaanniemi, S.; Rajala, U. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism, 2008, 57, 1130-1134.
235. Thorand, B.; Zierer, A.; Baumert, J.; Meisinger, C.; Herder, C.; Koenig, W. Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984-2002. Diabet Med, 27, 1004-1011.
236. Zhu, N.; Pankow, J. S.; Ballantyne, C. M.; Couper, D.; Hoogeveen, R. C.; Pereira, M.; Duncan, B. B.; Schmidt, M. I. High-molecularweight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab, 95, 5097-5104.
237. Fagerberg, B.; Kellis, D.; Bergstrom, G.; Behre, C. J. Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J Intern Med, 269, 636-643.
238. Li, F.; Zhao, T.; Wen, X. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: a pilot study. Diabetes Res Clin Pract, 94, 186-192.
239. Kacso, I. M.; Bondor, C. I.; Kacso, G. Plasma adiponectin is related to the progression of kidney disease in type 2 diabetes patients. Scand J Clin Lab Invest, 72, 333-339.
240. Sattar, N.; Nelson, S. M. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab, 2008, 93, 3299-3301.
241. Frystyk, J.; Tarnow, L.; Hansen, T. K.; Parving, H. H.; Flyvbjerg, A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 2005, 48, 1911-1918.
242. Lindstrom, T.; Frystyk, J.; Hedman, C. A.; Flyvbjerg, A.; Arnqvist, H. J. Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration. Clin Endocrinol (Oxf), 2006, 65, 776-782.
243. Zoccali, C.; Mallamaci, F.; Tripepi, G.; Benedetto, F. A.; Cutrupi, S.; Parlongo, S.; Malatino, L. S.; Bonanno, G.; Seminara, G.; Rapisarda, F.; Fatuzzo, P.; Buemi, M.; Nicocia, G.; Tanaka, S.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol, 2002, 13, 134-141.
244. Leth, H.; Andersen, K. K.; Frystyk, J.; Tarnow, L.; Rossing, P.; Parving, H. H.; Flyvbjerg, A. Elevated levels of high-molecularweight adiponectin in type 1 diabetes. J Clin Endocrinol Metab, 2008, 93, 3186-3191.
245. Forsblom, C.; Thomas, M. C.; Moran, J.; Saraheimo, M.; Thorn, L.; Waden, J.; Gordin, D.; Frystyk, J.; Flyvbjerg, A.; Groop, P. H. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med, 270, 346-355.
246. Jorsal, A.; Tarnow, L.; Frystyk, J.; Lajer, M.; Flyvbjerg, A.; Parving, H. H.; Vionnet, N.; Rossing, P. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int, 2008, 74, 649-654.
247. Prior, S. L.; Tang, T. S.; Gill, G. V.; Bain, S. C.; Stephens, J. W. Adiponectin, total antioxidant status, and urine albumin excretion in the low-risk Golden Years type 1 diabetes mellitus cohort. Metabolism, 60, 173-179.
248. McEntegart MB, Awede B, Petrie MC et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriureticpeptide. EurHeart J 2007; 7:829-35.
249. Cook, J. R.; Semple, R. K. Hypoadiponectinemia-cause or consequence of human insulin resistance? J Clin Endocrinol Metab, 95, 1544-1554.
250. Abi Khalil, C.; Mohammedi, K.; Aubert, R.; Travert, F.; Hadjadj, S.; Roussel, R.; Fumeron, F.; Marre, M. Intensifying glycaemic control with insulin reduces adiponectin and its HMW isoform moderately in type 2, but not in type 1, diabetes. Diabetes Metab, 37, 259-261.
251. Tabak, A. G.; Brunner, E. J.; Miller, M. A.; Karanam, S.; McTernan, P. G.; Cappuccio, F. P.; Witte, D. R. Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res, 2009, 41, 626-629.
252. Kanaya, A. M.; Wassel Fyr, C.; Vittinghoff, E.; Harris, T. B.; Park, S. W.; Goodpaster, B. H.; Tylavsky, F.; Cummings, S. R. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med, 2006, 166, 350-356.
253. Koenig, W.; Khuseyinova, N.; Baumert, J.; Meisinger, C.; Lowel, H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middleaged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol, 2006, 48, 1369-1377.
254. Nakashima, R.; Kamei, N.; Yamane, K.; Nakanishi, S.; Nakashima, A.; Kohno, N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab, 2006, 91, 3873-3877.
255. Duncan, B. B.; Schmidt, M. I.; Pankow, J. S.; Bang, H.; Couper, D.; Ballantyne, C. M.; Hoogeveen, R. C.; Heiss, G. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes, 2004, 53, 2473-2478.
256. Mather, K. J.; Funahashi, T.; Matsuzawa, Y.; Edelstein, S.; Bray, G. A.; Kahn, S. E.; Crandall, J.; Marcovina, S.; Goldstein, B.; Goldberg, R. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes, 2008, 57, 980-986.
257. Choi, K. M.; Lee, J.; Lee, K. W.; Seo, J. A.; Oh, J. H.; Kim, S. G.; Kim, N. H.; Choi, D. S.; Baik, S. H. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf), 2004, 61, 75-80.
258. Lindsay, R. S.; Funahashi, T.; Hanson, R. L.; Matsuzawa, Y.; Tanaka, S.; Tataranni, P. A.; Knowler, W. C.; Krakoff, J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 2002, 360, 57-58.
259. Haidar, Y. M.; Cosman, B. C. Obesity epidemiology. Clin Colon Rectal Surg, 24, 205-210.
260. Jee, S. H.; Sull, J. W.; Park, J.; Lee, S. Y.; Ohrr, H.; Guallar, E.; Samet, J. M. Body-mass index and mortality in Korean men and women. N Engl J Med, 2006, 355, 779-787.
261. Lawlor, D. A.; Song, Y. M.; Sung, J.; Ebrahim, S.; Smith, G. D. The association of smoking and cardiovascular disease in a population with low cholesterol levels: a study of 648,346 men from the Korean national health system prospective cohort study. Stroke, 2008, 39, 760-767.
262. Stewart, S. T.; Cutler, D. M.; Rosen, A. B. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med, 2009, 361, 2252-2260.
263. Wexler, D. J.; Hu, F. B.; Manson, J. E.; Rifai, N.; Meigs, J. B. Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity. Obes Res, 2005, 13, 1772-1783.
264. Yokota, T.; Oritani, K.; Takahashi, I.; Ishikawa, J.; Matsuyama, A.; Ouchi, N.; Kihara, S.; Funahashi, T.; Tenner, A. J.; Tomiyama, Y.; Matsuzawa, Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, 96, 1723-1732.
265. Ouchi, N.; Kihara, S.; Funahashi, T.; Nakamura, T.; Nishida, M.; Kumada, M.; Okamoto, Y.; Ohashi, K.; Nagaretani, H.; Kishida, K.; Nishizawa, H.; Maeda, N.; Kobayashi, H.; Hiraoka, H.; Matsuzawa, Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation, 2003, 107, 671-674.
266. Snehalatha, C.; Mukesh, B.; Simon, M.; Viswanathan, V.; Haffner, S. M.; Ramachandran, A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care, 2003, 26, 3226-3229.
267. Pischon, T.; Girman, C. J.; Hotamisligil, G. S.; Rifai, N.; Hu, F. B.; Rimm, E. B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004, 291, 1730-1737.
268. Jo, J.; Sull, J. W.; Park, E. J.; Jee, S. H. Effects of smoking and obesity on the association between CDH13 (rs3865188) and adiponectin among Korean men: the KARE study. Obesity (Silver Spring), 20, 1683-1687.
269. Nayak, B. S.; Ramsingh, D.; Gooding, S.; Legall, G.; Bissram, S.; Mohammed, A.; Raychaudhuri, A.; Sahadeo, B.; Pandohie, V.; Figaro, K. Plasma adiponectin levels are related to obesity, inflammation, blood lipids and insulin in type 2 diabetic and nondiabetic Trinidadians. Prim Care Diabetes, 4, 187-192.
270. Behre, C. J. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest, 2007, 67, 449-458.
271. Pannacciulli, N.; Vettor, R.; Milan, G.; Granzotto, M.; Catucci, A.; Federspil, G.; De Giacomo, P.; Giorgino, R.; De Pergola, G. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab, 2003, 88, 1748-1752.
272. Delporte, M. L.; Brichard, S. M.; Hermans, M. P.; Beguin, C.; Lambert, M. Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf), 2003, 58, 22-29.
273. Sinorita, H.; Asdie, R. H.; Pramono, R. B.; Purnama, L. B.; Asdie, A. H. Leptin, adiponectin and resistin concentration in obesity class I and II at Sardjito Hospital Yogyakarta. Acta Med Indones, 42, 74-77.
274. Conroy, S. M.; Chai, W.; Lim, U.; Franke, A. A.; Cooney, R. V.; Maskarinec, G. Leptin, adiponectin, and obesity among Caucasian and Asian women. Mediators Inflamm, 2011, 253580.
275. Meilleur, K. G.; Doumatey, A.; Huang, H.; Charles, B.; Chen, G.; Zhou, J.; Shriner, D.; Adeyemo, A.; Rotimi, C. Circulating adiponectin is associated with obesity and serum lipids in West Africans. J Clin Endocrinol Metab, 95, 3517-3521.
276. Sporrer, D.; Weber, M.; Wanninger, J.; Weigert, J.; Neumeier, M.; Stogbauer, F.; Lieberer, E.; Bala, M.; Kopp, A.; Schaffler, A.; Buechler, C. Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity. Eur J Clin Invest, 2009, 39, 671-679.
277. Odegaard, J. I.; Chawla, A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab, 2008, 4, 619-626.
278. R.S. Strauss, H.A. Polbck, Epidemic increase in childhood overweight, 1986-1998, JAMA, 2001, 286, 2845-2848.
279. Chu, N. F.; Wang, D. J.; Shieh, S. M. Obesity, leptin and blood pressure among children in Taiwan: the Taipei Children's Heart Study. Am J Hypertens, 2001, 14, 135-140.
280. Steinberger, J.; Steffen, L.; Jacobs, D. R., Jr.; Moran, A.; Hong, C. P.; Sinaiko, A. R. Relation of leptin to insulin resistance syndrome in children. Obes Res, 2003, 11, 1124-1130.
281. Hassink, S. G.; Sheslow, D. V.; de Lancey, E.; Opentanova, I.; Considine, R. V.; Caro, J. F. Serum leptin in children with obesity: relationship to gender and development. Pediatrics, 1996, 98, 201-203.
282. Stefan, N.; Bunt, J. C.; Salbe, A. D.; Funahashi, T.; Matsuzawa, Y.; Tataranni, P. A. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab, 2002, 87, 4652-4656.
283. Asayama, K.; Hayashibe, H.; Dobashi, K.; Uchida, N.; Nakane, T.; Kodera, K.; Shirahata, A.; Taniyama, M. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res, 2003, 11, 1072-1079.
284. Bahrami, H.; Bluemke, D. A.; Kronmal, R.; Bertoni, A. G.; Lloyd-Jones, D. M.; Shahar, E.; Szklo, M.; Lima, J. A. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol, 2008, 51, 1775-1783.
285. Wachtell, K.; Ibsen, H.; Olsen, M. H.; Borch-Johnsen, K.; Lindholm, L. H.; Mogensen, C. E.; Dahlof, B.; Devereux, R. B.; Beevers, G.; de Faire, U.; Fyhrquist, F.; Julius, S.; Kjeldsen, S. E.; Kristianson, K.; Lederballe-Pedersen, O.; Nieminen, M. S.; Okin, P. M.; Omvik, P.; Oparil, S.; Wedel, H.; Snapinn, S. M.; Aurup, P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med, 2003, 139, 901-906.
286. Sharma, K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int, 2009, 76, 145-148.
287. Cnop, M.; Havel, P. J.; Utzschneider, K. M.; Carr, D. B.; Sinha, M. K.; Boyko, E. J.; Retzlaff, B. M.; Knopp, R. H.; Brunzell, J. D.; Kahn, S. E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003, 46, 459-469.
288. Statnick, M. A.; Beavers, L. S.; Conner, L. J.; Corominola, H.; Johnson, D.; Hammond, C. D.; Rafaeloff-Phail, R.; Seng, T.; Suter, T. M.; Sluka, J. P.; Ravussin, E.; Gadski, R. A.; Caro, J. F. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res, 2000, 1, 81-88.
289. Fisher, F. M.; McTernan, P. G.; Valsamakis, G.; Chetty, R.; Harte, A. L.; Anwar, A. J.; Starcynski, J.; Crocker, J.; Barnett, A. H.; McTernan, C. L.; Kumar, S. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res, 2002, 34, 650-654.
290. Kim, C.; Park, J.; Kang, E.; Ahn, C.; Cha, B.; Lim, S.; Kim, K.; Lee, H. Comparison of body fat composition and serum adiponectin levels in diabetic obesity and non-diabetic obesity. Obesity (Silver Spring), 2006, 14, 1164-1171.
291. Baratta, R.; Amato, S.; Degano, C.; Farina, M. G.; Patane, G.; Vigneri, R.; Frittitta, L. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab, 2004, 89, 2665-2671.
292. Bobbert, T.; Rochlitz, H.; Wegewitz, U.; Akpulat, S.; Mai, K.; Weickert, M. O.; Mohlig, M.; Pfeiffer, A. F.; Spranger, J. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes, 2005, 54, 2712-2719.
293. Illan-Gomez, F.; Gonzalvez-Ortega, M.; Orea-Soler, I.; Alcaraz-Tafalla, M. S.; Aragon-Alonso, A.; Pascual-Diaz, M.; Perez-Paredes, M.; Lozano-Almela, M. L. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg, 22, 950-955.
294. Holmes, R. M.; Yi, Z.; De Filippis, E.; Berria, R.; Shahani, S.; Sathyanarayana, P.; Sherman, V.; Fujiwara, K.; Meyer, C.; Christ-Roberts, C.; Hwang, H.; Finlayson, J.; Dong, L. Q.; Mandarino, L. J.; Bajaj, M. Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling. Diabetologia, 54, 2122-2131.
295. Viguerie, N.; Vidal, H.; Arner, P.; Holst, C.; Verdich, C.; Avizou, S.; Astrup, A.; Saris, W. H.; Macdonald, I. A.; Klimcakova, E.; Clement, K.; Martinez, A.; Hoffstedt, J.; Sorensen, T. I.; Langin, D. Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia, 2005, 48, 123-131.
296. Garaulet, M.; Viguerie, N.; Porubsky, S.; Klimcakova, E.; Clement, K.; Langin, D.; Stich, V. Adiponectin gene expression and plasma values in obese women during very-low-calorie diet. Relationship with cardiovascular risk factors and insulin resistance. J Clin Endocrinol Metab, 2004, 89, 756-760.
297. Xydakis, A. M.; Case, C. C.; Jones, P. H.; Hoogeveen, R. C.; Liu, M. Y.; Smith, E. O.; Nelson, K. W.; Ballantyne, C. M. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab, 2004, 89, 2697-2703.
298. Wolfe, B. E.; Jimerson, D. C.; Orlova, C.; Mantzoros, C. S. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf), 2004, 61, 332-338.
299. Weyer, C.; Funahashi, T.; Tanaka, S.; Hotta, K.; Matsuzawa, Y.; Pratley, R. E.; Tataranni, P. A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001, 86, 1930-1935.
300. Behre, C. J.; Fagerberg, B.; Hulten, L. M.; Hulthe, J. The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. Metabolism, 2005, 54, 439-444.
301. Tschritter, O.; Fritsche, A.; Thamer, C.; Haap, M.; Shirkavand, F.; Rahe, S.; Staiger, H.; Maerker, E.; Haring, H.; Stumvoll, M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 2003, 52, 239-243.
302. Blumer, R. M.; van Roomen, C. P.; Meijer, A. J.; Houben-Weerts, J. H.; Sauerwein, H. P.; Dubbelhuis, P. F. Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes. Metabolism, 2008, 57, 1655-1662.
303. Halleux, C. M.; Takahashi, M.; Delporte, M. L.; Detry, R.; Funahashi, T.; Matsuzawa, Y.; Brichard, S. M. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun, 2001, 288, 1102-1107.
304. Pereira, R. I.; Leitner, J. W.; Erickson, C.; Draznin, B. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase. Life Sci, 2008, 83, 638-643.
305. Fasshauer, M.; Klein, J.; Neumann, S.; Eszlinger, M.; Paschke, R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 2002, 290, 1084-1089.
306. Pereira, R. I.; Draznin, B. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism, 2005, 54, 1636-1643.
307. Imagawa, A.; Funahashi, T.; Nakamura, T.; Moriwaki, M.; Tanaka, S.; Nishizawa, H.; Sayama, K.; Uno, S.; Iwahashi, H.; Yamagata, K.; Miyagawa, J.; Matsuzawa, Y. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care, 2002, 25, 1665-1666.
308. Semple, R. K.; Soos, M. A.; Luan, J.; Mitchell, C. S.; Wilson, J. C.; Gurnell, M.; Cochran, E. K.; Gorden, P.; Chatterjee, V. K.; Wareham, N. J.; O'Rahilly, S. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab, 2006, 91, 3219-3223.
309. Basu, R.; Pajvani, U. B.; Rizza, R. A.; Scherer, P. E. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes, 2007, 56, 2174-2177.
310. Lloyd-Jones, D.; Adams, R. J.; Brown, T. M.; Carnethon, M.; Dai, S.; De Simone, G.; Ferguson, T. B.; Ford, E.; Furie, K.; Gillespie, C.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, P. M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M. M.; Meigs, J.; Mozaffarian, D.; Mussolino, M.; Nichol, G.; Roger, V. L.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N. D.; Wylie-Rosett, J. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation, 121, 948-954.
311. Fonarow, G. C. The global burden of atherosclerotic vascular disease. Nat Clin Pract Cardiovasc Med, 2007, 4, 530-531.
312. Steg, P. G.; Bhatt, D. L.; Wilson, P. W.; D'Agostino, R., Sr.; Ohman, E. M.; Rother, J.; Liau, C. S.; Hirsch, A. T.; Mas, J. L.; Ikeda, Y.; Pencina, M. J.; Goto, S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA, 2007, 297, 1197-1206.
313. Tunstall-Pedoe, H.; Vanuzzo, D.; Hobbs, M.; Mahonen, M.; Cepaitis, Z.; Kuulasmaa, K.; Keil, U. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet, 2000, 355, 688-700.
314. World Health Organization The global burden of disease - 2004 update. 2004.
315. Ai, M.; Otokozawa, S.; Asztalos, B. F.; White, C. C.; Cupples, L. A.; Nakajima, K.; Lamon-Fava, S.; Wilson, P. W.; Matsuzawa, Y.; Schaefer, E. J. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis, 217, 543-548.
316. Chen, C. Y.; Asakura, M.; Asanuma, H.; Hasegawa, T.; Tanaka, J.; Toh, N.; Min, K. D.; Kanzaki, H.; Takahama, H.; Amaki, M.; Itoh, Y.; Ichien, G.; Okumoto, Y.; Funahashi, T.; Kim, J.; Kitakaze, M. Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels. Hypertens Res, 35, 843-848.
317. Sattar, N.; Wannamethee, G.; Sarwar, N.; Tchernova, J.; Cherry, L.; Wallace, A. M.; Danesh, J.; Whincup, P. H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006, 114, 623-629.
318. Zhang, H.; Mo, X.; Hao, Y.; Huang, J.; Lu, X.; Cao, J.; Gu, D. Adiponectin Levels and Risk of Coronary Heart Disease: A Metaanalysis of Prospective Studies. Am J Med Sci.
319. Karakas, M.; Zierer, A.; Herder, C.; Baumert, J.; Meisinger, C.; Koenig, W.; Thorand, B. Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis, 209, 220-225.
320. Khalili, P.; Flyvbjerg, A.; Frystyk, J.; Lundin, F.; Jendle, J.; Engstrom, G.; Nilsson, P. M. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, longterm follow-up study. Diabetes Metab, 36, 137-143.
321. Pischon, T.; Hu, F. B.; Girman, C. J.; Rifai, N.; Manson, J. E.; Rexrode, K. M.; Rimm, E. B. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis, 219, 322-329.
322. Hirata, A.; Kishida, K.; Nakatsuji, H.; Kobayashi, H.; Funahashi, T.; Shimomura, I. High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics. Metabolism.
323. Hung, W. C.; Wang, C. P.; Lu, L. F.; Yu, T. H.; Chiu, C. A.; Chung, F. M.; Chen, H. J.; Houng, J. Y.; Shin, S. J.; Lee, Y. J. Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 diabetic patients with coronary artery disease. Endocr J, 57, 793-802.
324. Mikkelsen, M. M.; Hansen, T. K.; Gjedsted, J.; Andersen, N. H.; Christensen, T. D.; Hjortdal, V. E.; Johnsen, S. P. Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: a prospective follow-up study. J Cardiothorac Surg, 5, 129.
325. Hascoet, S.; Elbaz, M.; Bongard, V.; Bouisset, F.; Verdier, C.; Vindis, C.; Annelise, G.; Taraszkiewicz, D.; Perret, B.; Galinier, M.; Carrie, D.; Ferrieres, J.; Ruidavets, J. B. Adiponectin and Long-Term Mortality in Coronary Artery Disease Participants and Controls. Arterioscler Thromb Vasc Biol.
326. Stamatelopoulos, K.; Karatzi, K.; Sidossis, L. S. Noninvasive methods for assessing early markers of atherosclerosis: the role of body composition and nutrition. Curr Opin Clin Nutr Metab Care, 2009, 12, 467-473.
327. Uthoff, H.; Staub, D.; Meyerhans, A.; Hochuli, M.; Bundi, B.; Schmid, H. P.; Frauchiger, B. Intima-media thickness and carotid resistive index: progression over 6 years and predictive value for cardiovascular events. Ultraschall Med, 2008, 29, 604-610.
328. Vlachopoulos, C.; Aznaouridis, K.; Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol, 55, 1318-1327.
329. Imatoh, T.; Miyazaki, M.; Kadowaki, K.; Tanihara, S.; Akashi, C.; Une, H. Measurement of high-molecular-weight adiponectin is not useful in assessing coronary stenosis. Clin Chem Lab Med, 50, 741-745.
330. Kunita, E.; Yamamoto, H.; Kitagawa, T.; Ohashi, N.; Utsunomiya, H.; Oka, T.; Horiguchi, J.; Awai, K.; Kihara, Y. Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation. Circ J, 76, 1687-1696.
331. Sattar, N.; Watt, P.; Cherry, L.; Ebrahim, S.; Davey Smith, G.; Lawlor, D. A. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J Clin Endocrinol Metab, 2008, 93, 1846-1849.
332. Hwang, J. J.; Yang, W. S.; Chiang, F. T.; Chen, M. F.; Lin, H. J.; Huang, P. J.; Hsu, S. H.; Lai, S. K.; Wu, Y. W. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis, 2009, 204, 293-297.
333. Persson, J.; Lindberg, K.; Gustafsson, T. P.; Eriksson, P.; Paulsson-Berne, G.; Lundman, P. Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med, 268, 194-205.
334. Lindberg, S.; Pedersen, S. H.; Mogelvang, R.; Bjerre, M.; Frystyk, J.; Flyvbjerg, A.; Galatius, S.; Jensen, J. S. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol, 109, 492-496.
335. Wilson, S. R.; Sabatine, M. S.; Wiviott, S. D.; Ray, K. K.; De Lemos, J. A.; Zhou, S.; Rifai, N.; Cannon, C. P.; Morrow, D. A. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J, 161, 1147-1155 e1141.
336. Ohashi, T.; Shibata, R.; Morimoto, T.; Kanashiro, M.; Ishii, H.; Ichimiya, S.; Hiro, T.; Miyauchi, K.; Nakagawa, Y.; Yamagishi, M.; Ozaki, Y.; Kimura, T.; Daida, H.; Murohara, T.; Matsuzaki, M. Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. Atherosclerosis, 212, 237-242.
337. Kuklina, E. V.; Tong, X.; George, M. G.; Bansil, P. Epidemiology and prevention of stroke: a worldwide perspective. Expert Rev Neurother, 12, 199-208.
338. Mukherjee, D.; Patil, C. G. Epidemiology and the global burden of stroke. World Neurosurg, 76, S85-90.
339. Kinlay, S. Changes in stroke epidemiology, prevention, and treatment. Circulation, 124, e494-496.
340. Zhang, B. C.; Liu, W. J.; Che, W. L.; Xu, Y. W. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. Clin Endocrinol (Oxf), 77, 370-378.
341. Chen, M. P.; Tsai, J. C.; Chung, F. M.; Yang, S. S.; Hsing, L. L.; Shin, S. J.; Lee, Y. J. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol, 2005, 25, 821-826.
342. O'Leary, D. H.; Polak, J. F.; Kronmal, R. A.; Manolio, T. A.; Burke, G. L.; Wolfson, S. K., Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med, 1999, 340, 14-22.
343. Dullaart RP, Kappelle PJ, Dallinga-Thie GM. Carotid intima media thickness is associated with plasma adiponectin but not with the leptin: adiponectin ratio independently of metabolic syndrome. Atherosclerosis. 2010, 211, 393-396.
344. Gardener, H.; Sjoberg, C.; Crisby, M.; Goldberg, R.; Mendez, A.; Wright, C. B.; Elkind, M. S.; Sacco, R. L.; Rundek, T. Adiponectin and carotid intima-media thickness in the northern Manhattan study. Stroke, 43, 1123-1125.
345. Prugger, C.; Luc, G.; Haas, B.; Arveiler, D.; Machez, E.; Ferrieres, J.; Ruidavets, J. B.; Bingham, A.; Montaye, M.; Amouyel, P.; Yarnell, J.; Kee, F.; Ducimetiere, P.; Empana, J. P. Adipocytokines and the risk of ischemic stroke: the PRIME Study. Ann Neurol, 71, 478-486.
346. Rajpathak, S. N.; Kaplan, R. C.; Wassertheil-Smoller, S.; Cushman, M.; Rohan, T. E.; McGinn, A. P.; Wang, T.; Strickler, H. D.; Scherer, P. E.; Mackey, R.; Curb, D.; Ho, G. Y. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative. Stroke, 42, 1813-1820.
347. Matsumoto, M.; Ishikawa, S.; Kajii, E. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke, 2008, 39, 323-328.
348. Ogorodnikova, A. D.; Wassertheil-Smoller, S.; Mancuso, P.; Sowers, M. R.; Rajpathak, S. N.; Allison, M. A.; Baird, A. E.; Rodriguez, B.; Wildman, R. P. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke, 41, 1376-1381.
349. Nagasawa, H.; Yokota, C.; Toyoda, K.; Ito, A.; Minematsu, K. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J Neurol Sci, 304, 102-106.
350. Baranowska, B.; Kochanowski, J.; Grudniak, M.; Baranowska-Bik, A.; Wolinska-Witort, E.; Martynska, L.; Bik, W. Decreased total serum adiponectin and its isoforms in women with acute ischemic stroke. Neuro Endocrinol Lett, 32, 711-715.
351. Persson, J.; Folkersen, L.; Ekstrand, J.; Helleberg, J.; Gabrielsen, A.; Lundman, P.; Hedin, U.; Paulsson-Berne, G. High plasma adiponectin concentration is associated with all-cause mortality in patients with carotid atherosclerosis. Atherosclerosis, 225, 491-496.
352. Anker, S. D.; Steinborn, W.; Strassburg, S. Cardiac cachexia. Ann Med, 2004, 36, 518-529.
353. Clark, A. L.; Poole-Wilson, P. A.; Coats, A. J. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol, 1996, 28, 1092-1102.
354. Conraads, V. M.; Hoymans, V. Y.; Vrints, C. J. Heart failure and cachexia: insights offered from molecular biology. Front Biosci, 2008, 13, 325-335.
355. Roger, V. L.; Go, A. S.; Lloyd-Jones, D. M.; Benjamin, E. J.; Berry, J. D.; Borden, W. B.; Bravata, D. M.; Dai, S.; Ford, E. S.; Fox, C. S.; Fullerton, H. J.; Gillespie, C.; Hailpern, S. M.; Heit, J. A.; Howard, V. J.; Kissela, B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Makuc, D. M.; Marcus, G. M.; Marelli, A.; Matchar, D. B.; Moy, C. S.; Mozaffarian, D.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Soliman, E. Z.; Sorlie, P. D.; Sotoodehnia, N.; Turan, T. N.; Virani, S. S.; Wong, N. D.; Woo, D.; Turner, M. B. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation, 125, e2-e220.
356. Heidenreich P.A., Trogdon J.G., Khavjou O.A., et al: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation, 2011, 123. 933-944.
357. George, J.; Patal, S.; Wexler, D.; Sharabi, Y.; Peleg, E.; Kamari, Y.; Grossman, E.; Sheps, D.; Keren, G.; Roth, A. Circulating adiponectin concentrations in patients with congestive heart failure. Heart, 2006, 92, 1420-1424.
358. Wannamethee, S. G.; Whincup, P. H.; Lennon, L.; Sattar, N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med, 2007, 167, 1510-1517.
359. Dieplinger, B.; Gegenhuber, A.; Poelz, W.; Haltmayer, M.; Mueller, T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem, 2009, 42, 1190-1193.
360. Haugen, E.; Furukawa, Y.; Isic, A.; Fu, M. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study. Int J Cardiol, 2008, 125, 216-219.
361. Matsumoto, M.; Lee-Kawabata, M.; Tsujino, T.; Naito, Y.; Ezumi, A.; Sakoda, T.; Ohyanagi, M.; Shimomura, I.; Masuyama, T. Decrease in serum adiponectin levels in response to treatment predicts good prognosis in acute decompensated heart failure. J Clin Hypertens (Greenwich), 12, 900-904.
362. Ohara, T.; Hashimura, K.; Asakura, M.; Ogai, A.; Amaki, M.; Hasegawa, T.; Kanzaki, H.; Sonoda, M.; Nishizawa, H.; Funahashi, T.; Kitakaze, M. Dynamic changes in plasma total and high molecular weight adiponectin levels in acute heart failure. J Cardiol, 58, 181-190.
363. Biolo, A.; Shibata, R.; Ouchi, N.; Kihara, S.; Sonoda, M.; Walsh, K.; Sam, F. Determinants of adiponectin levels in patients with chronic systolic heart failure. Am J Cardiol, 105, 1147-1152.
364. Tsukamoto, O.; Fujita, M.; Kato, M.; Yamazaki, S.; Asano, Y.; Ogai, A.; Okazaki, H.; Asai, M.; Nagamachi, Y.; Maeda, N.; Shintani, Y.; Minamino, T.; Asakura, M.; Kishimoto, I.; Funahashi, T.; Tomoike, H.; Kitakaze, M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol, 2009, 53, 2070-2077.
365. Lau W, Tao L, Wang Y, et al. Systemic adiponectin malfunction as a risk factor for cardiovascular disease. Antioxid Redox Signal. 2010, in press. This review summarizes the major biologic functions and intracellular pathways of adiponectin and elaborates current knowledge on adiponectin malfunction in cardiovascular disease.
366. Krause, M. P.; Liu, Y.; Vu, V.; Chan, L.; Xu, A.; Riddell, M. C.; Sweeney, G.; Hawke, T. J. Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and function. Am J Physiol Cell Physiol, 2008, 295, C203-212.
367. Skurk, C.; Wittchen, F.; Suckau, L.; Witt, H.; Noutsias, M.; Fechner, H.; Schultheiss, H. P.; Poller, W. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J, 2008, 29, 1168-1180.
368. Takano, H.; Obata, J. E.; Kodama, Y.; Kitta, Y.; Nakamura, T.; Mende, A.; Kawabata, K.; Saito, Y.; Fujioka, D.; Kobayashi, T.; Yano, T.; Sano, K.; Kugiyama, K. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol, 2009, 132, 221-226.
369. Kalantar-Zadeh, K.; Block, G.; Horwich, T.; Fonarow, G. C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol, 2004, 43, 1439-1444.
370. Kintscher, U. Does adiponectin resistance exist in chronic heart failure? Eur Heart J, 2007, 28, 1676-1677.
371. Sekiguchi, K.; Tian, Q.; Ishiyama, M.; Burchfield, J.; Gao, F.; Mann, D. L.; Barger, P. M. Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. Am J Physiol Heart Circ Physiol, 2007, 292, H1443-1451.
372. Van Berendoncks, A. M.; Garnier, A.; Beckers, P.; Hoymans, V. Y.; Possemiers, N.; Fortin, D.; Martinet, W.; Van Hoof, V.; Vrints, C. J.; Ventura-Clapier, R.; Conraads, V. M. Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail, 3, 185-194.
373. Ueshima, H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb, 2007, 14, 278-286.
374. Wipfli, H.; Samet, J. M. Global economic and health benefits of tobacco control: part 1. Clin Pharmacol Ther, 2009, 86, 263-271.
375. Wipfli, H.; Samet, J. M. Global economic and health benefits of tobacco control: part 2. Clin Pharmacol Ther, 2009, 86, 272-280.
376. Kotani, K.; Hazama, A.; Hagimoto, A.; Saika, K.; Shigeta, M.; Katanoda, K.; Nakamura, M. Adiponectin and smoking status: a systematic review. J Atheroscler Thromb, 19, 787-794.
377. Tsai, J. S.; Guo, F. R.; Chen, S. C.; Lue, B. H.; Lee, L. T.; Huang, K. C.; Chen, C. Y.; Hung, S. H.; Chuang, L. M. Changes of serum adiponectin and soluble intercellular adhesion molecule-1 concentrations after smoking cessation. Clin Chem Lab Med, 50, 1063-1069.
378. Adamczak, M.; Rzepka, E.; Chudek, J.; Wiecek, A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf), 2005, 62, 114-118.
379. Iwashima, Y.; Katsuya, T.; Ishikawa, K.; Kida, I.; Ohishi, M.; Horio, T.; Ouchi, N.; Ohashi, K.; Kihara, S.; Funahashi, T.; Rakugi, H.; Ogihara, T. Association of hypoadiponectinemia with smoking habit in men. Hypertension, 2005, 45, 1094-1100.
380. Ishizaka, N.; Ishizaka, Y.; Toda, E.; Hashimoto, H.; Nagai, R.; Yamakado, M. Association between cigarette smoking, metabolic syndrome, and carotid arteriosclerosis in Japanese individuals. Atherosclerosis, 2005, 181, 381-388.
381. Nakanishi, N.; Takatorige, T.; Suzuki, K. Cigarette smoking and the risk of the metabolic syndrome in middle-aged Japanese male office workers. Ind Health, 2005, 43, 295-301.
382. Miyatake, N.; Wada, J.; Kawasaki, Y.; Nishii, K.; Makino, H.; Numata, T. Relationship between metabolic syndrome and cigarette smoking in the Japanese population. Intern Med, 2006, 45, 1039-1043.
383. Wilsgaard, T.; Jacobsen, B. K. Lifestyle factors and incident metabolic syndrome. The Tromso Study 1979-2001. Diabetes Res Clin Pract, 2007, 78, 217-224.
384. Okamoto, Y.; Arita, Y.; Nishida, M.; Muraguchi, M.; Ouchi, N.; Takahashi, M.; Igura, T.; Inui, Y.; Kihara, S.; Nakamura, T.; Yamashita, S.; Miyagawa, J.; Funahashi, T.; Matsuzawa, Y. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res, 2000, 32, 47-50.
385. Sniderman, A. D.; Furberg, C. D. Age as a modifiable risk factor for cardiovascular disease. Lancet, 2008, 371, 1547-1549.
386. Laughlin, G. A.; Barrett-Connor, E.; May, S.; Langenberg, C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol, 2007, 165, 164-174.
387. Poehls, J.; Wassel, C. L.; Harris, T. B.; Havel, P. J.; Swarbrick, M. M.; Cummings, S. R.; Newman, A. B.; Satterfield, S.; Kanaya, A. M. Association of adiponectin with mortality in older adults: the Health, Aging, and Body Composition Study. Diabetologia, 2009, 52, 591-595.
388. Kizer, J. R.; Arnold, A. M.; Strotmeyer, E. S.; Ives, D. G.; Cushman, M.; Ding, J.; Kritchevsky, S. B.; Chaves, P. H.; Hirsch, C. H.; Newman, A. B. Change in circulating adiponectin in advanced old age: determinants and impact on physical function and mortality. The Cardiovascular Health Study All Stars Study. J Gerontol A Biol Sci Med Sci, 65, 1208-1214.
389. Schautz, B.; Later, W.; Heller, M.; Peters, A.; Muller, M. J.; Bosy-Westphal, A. Impact of age on leptin and adiponectin independent of adiposity. Br J Nutr, 108, 363-370.
390. Isobe, T.; Saitoh, S.; Takagi, S.; Takeuchi, H.; Chiba, Y.; Katoh, N.; Shimamoto, K. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol, 2005, 153, 91-98.
391. Gabriely, I.; Barzilai, N. The role of fat cell derived peptides in age-related metabolic alterations. Mech Ageing Dev, 2001, 122, 1565-1576.
392. Antonopoulos, A. S.; Lee, R.; Margaritis, M.; Antoniades, C. Adiponectin as a regulator of vascular redox state: therapeutic implications. Recent Pat Cardiovasc Drug Discov, 6, 78-88.
393. Goldberger, J. J.; Cain, M. E.; Hohnloser, S. H.; Kadish, A. H.; Knight, B. P.; Lauer, M. S.; Maron, B. J.; Page, R. L.; Passman, R. S.; Siscovick, D.; Stevenson, W. G.; Zipes, D. P. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation, 2008, 118, 1497-1518.
394. Liao, Y. C.; Liang, K. W.; Lee, W. J.; Lee, W. L.; Lee, I. T.; Wang, J. S.; Ting, C. T.; Sheu, W. H. Leptin to adiponectin ratio as a useful predictor for cardiac syndrome X. Biomarkers.
395. Rienstra, M.; Sun, J. X.; Lubitz, S. A.; Frankel, D. S.; Vasan, R. S.; Levy, D.; Magnani, J. W.; Sullivan, L. M.; Meigs, J. B.; Ellinor, P. T.; Benjamin, E. J. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J, 163, 119-124 e111.
396. Sun, X.; Boyce, S. W.; Hill, P. C.; Bafi, A. S.; Xue, Z.; Lindsay, J.; Corso, P. J. Association of body mass index with new-onset atrial fibrillation after coronary artery bypass grafting operations. Ann Thorac Surg, 91, 1852-1858.
397. Kourliouros, A.; Karastergiou, K.; Nowell, J.; Gukop, P.; Tavakkoli Hosseini, M.; Valencia, O.; Mohamed Ali, V.; Jahangiri, M. Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. Eur J Cardiothorac Surg, 39, 228-232.